Related Experiment Video
Updated: May 17, 2026
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
[Efficiency of fenticonazole for the treatment of vaginal candidiasis]
Introduction:
Uncomplicated vulvovaginal candidiasis appears in 75% women of reproductive age. The most frequent causes are Candida albicans (85-95%) or C. glabrata, and infrequently C. krusei, C. tropicalis, C. parapsilosis, C. pseudotropicalis, etc.
Objective:
The aim of the study was to investigate efficiency and safety of fenticonazole for vaginal candidiasis treatment.
Methods:
Therapeutic effect of a single 600 mg fenticonasole vaginal capsule was observed in 417 women, aged 16-67, in five centers in Serbia. In all women, before the treatment, vaginal candidiasis was confirmed by testing of vaginal smear. Based on smear findings and associated symptoms observed on the 7th and 28th day after therapy administration, treatment results were evaluated. On the next day after drug application the patients recorded by using a questionnaire their own feelings on withdrawal symptoms and possible side effects in the period prior to the first control.
Results:
Control after seven days showed a statistically significant decrease of symptoms. In 385 women, vaginal smear was found negative to yeast and yeast blastospores. Within the first seven days after treatment 84 women had to repeat therapy due to the persistence of symptoms or positive vaginal smear. After 28 days we recorded full recovery in 392 patients, clinical improvement in eight, no change in 16, and deterioration in one patient only. Side effects were very seldom, mostly in the form of a slight redness of the vulva and vagina, and mild itching during several days.
Conclusion:
Our observations confirmed good efficacy and safety of fenticonazole in the treatment of vaginal candidiasis.
Insights
Fenticonazole effectively treated vaginal candidiasis in women, demonstrating high recovery rates and minimal side effects. This study confirms its safety and efficacy for yeast infection management.
Area of Science:
- Mycology
- Pharmacology
- Gynecology
Context:
- Vulvovaginal candidiasis affects 75% of women of reproductive age.
- Candida albicans is the most common pathogen, but other Candida species can also cause infection.
- Effective treatment options are crucial for managing this prevalent condition.
Purpose:
- To evaluate the efficacy and safety of a single 600 mg fenticonazole vaginal capsule for treating vaginal candidiasis.
- To assess treatment outcomes based on clinical symptoms and vaginal smear results.
Summary:
- A study involving 417 women with vaginal candidiasis assessed the therapeutic effect of a single 600 mg fenticonazole vaginal capsule.
- After seven days, a significant decrease in symptoms was observed, with 385 women showing negative vaginal smears.
- Full recovery was achieved in 392 patients after 28 days, with very few reported side effects.
Impact:
- Fenticonazole demonstrates good efficacy and safety for treating vaginal candidiasis.
- The study supports fenticonazole as a reliable option for managing yeast infections.
- Minimal adverse effects suggest a favorable safety profile for patient use.
More Related Videos
06:50A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
Published on: September 16, 2022
07:19A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
Published on: October 21, 2010
Related Concept Videos
01:15Antifungal Agents
01:28Antimicrobial Effectiveness